Coverage
Filings
Zealand Pharma on Thursday reported a significant surge in revenue and profit for the first nine months of 2025, driven by its recent partnership with Roche, while also announcing it has paused development of its experimental obesity drug, dapiglutide.
Zealand Pharma's revenue and profit soared in the first half of 2025, a direct result of a major partnership with Roche to develop its new weight-loss drug candidate, petrelintide.
Zealand Pharma on Wednesday reported positive results from a mid-stage study of its experimental obesity drug, dapiglutide, showing an average body weight reduction of 11.6% over 28 weeks.
| New warrants granted to executive management under the existing incentive scheme | 30 Nov 2012 |
| Zealand Pharma to host a Capital Markets Day in New York | 27 Nov 2012 |
| Announcement of transactions in the company’s shares and related securities by executives and their related parties | 20 Nov 2012 |
| Zealand Pharma A/S - New warrants granted to executive management under the existing incentive scheme | 19 Nov 2012 |
| Zealand Pharma announces that once-daily Lyxumia®1 (lixisenatide) has received CHMP positive opinion for the treatment of adults with Type 2 diabetes in the EU | 16 Nov 2012 |